Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...

The ReSPECT-LM dose optimization trial benefits from a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT), the second largest public funding source for cancer ...

Genitourinary Tumor Study Ongoing with Active Screening and Enrollment MILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today ...

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals Genitourinary Tumor Study Ongoing with Active Screening and Enrollment ...

Welcome to the first edition of the Investing News Network's weekly round-up of Australia’s top-performing mining stocks on the ASX, starting with news in Australia's resource sector. This week ...

Immune checkpoint inhibitors provide durable clinical responses in multiple difficult-to-treat tumor types. The tumor microenvironment, tumor immunogenicity, antigen presentation, and classic ...

“As GBM, like most malignant cancers, is dependent on fermentation for energy synthesis and survival, the simultaneous restriction of fermentable fuels, such as glucose and glutamine, while elevating ...

The American-British consortium GBM Holdings has acquired the British division of one of the largest Russian brokerage companies BCS Prime Brokerage Ltd. This is reported in the GBM press release.